Brazil · Delayed Price · Currency is BRL BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of BRL 133.55 billion. The enterprise value is 55.32 billion.
| Market Cap | 133.55B |
| Enterprise Value | 55.32B |
Important Dates
The last earnings date was Tuesday, August 4, 2026.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.00% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 16.35% |
| Owned by Institutions (%) | 20.00% |
| Float | 108.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.51 |
| PB Ratio | 1.27 |
| P/TBV Ratio | 1.41 |
| P/FCF Ratio | 48.09 |
| P/OCF Ratio | 33.20 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 19.92 |
Financial Position
The company has a current ratio of 7.85, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.85 |
| Quick Ratio | 7.03 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.67 |
| Interest Coverage | -127.06 |
Financial Efficiency
Return on equity (ROE) is -9.30% and return on invested capital (ROIC) is -36.69%.
| Return on Equity (ROE) | -9.30% |
| Return on Assets (ROA) | -5.41% |
| Return on Invested Capital (ROIC) | -36.69% |
| Return on Capital Employed (ROCE) | -9.88% |
| Weighted Average Cost of Capital (WACC) | 11.17% |
| Revenue Per Employee | 2.01M |
| Profits Per Employee | -1.28M |
| Employee Count | 7,807 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.74 |
Taxes
In the past 12 months, BioNTech SE has paid 336.78 million in taxes.
| Income Tax | 336.78M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.59% in the last 52 weeks. The beta is 1.28, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -4.59% |
| 50-Day Moving Average | 30.60 |
| 200-Day Moving Average | 31.90 |
| Relative Strength Index (RSI) | 56.03 |
| Average Volume (20 Days) | 3,045 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.12 |
Income Statement
In the last 12 months, BioNTech SE had revenue of BRL 15.69 billion and -9.98 billion in losses. Loss per share was -40.27.
| Revenue | 15.69B |
| Gross Profit | 12.02B |
| Operating Income | -10.75B |
| Pretax Income | -9.64B |
| Net Income | -9.98B |
| EBITDA | -8.17B |
| EBIT | -10.75B |
| Loss Per Share | -40.27 |
Balance Sheet
The company has 79.69 billion in cash and 1.87 billion in debt, with a net cash position of 77.82 billion.
| Cash & Cash Equivalents | 79.69B |
| Total Debt | 1.87B |
| Net Cash | 77.82B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 105.10B |
| Book Value Per Share | 418.40 |
| Working Capital | 79.01B |
Cash Flow
In the last 12 months, operating cash flow was 4.02 billion and capital expenditures -1.25 billion, giving a free cash flow of 2.78 billion.
| Operating Cash Flow | 4.02B |
| Capital Expenditures | -1.25B |
| Depreciation & Amortization | 2.62B |
| Net Borrowing | 140.21M |
| Free Cash Flow | 2.78B |
| FCF Per Share | n/a |
Margins
Gross margin is 76.62%, with operating and profit margins of -68.57% and -63.64%.
| Gross Margin | 76.62% |
| Operating Margin | -68.57% |
| Pretax Margin | -61.49% |
| Profit Margin | -63.64% |
| EBITDA Margin | -52.11% |
| EBIT Margin | -68.57% |
| FCF Margin | 17.42% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.00% |
| Shareholder Yield | -3.00% |
| Earnings Yield | -7.47% |
| FCF Yield | 2.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 21, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Nov 21, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
BioNTech SE has an Altman Z-Score of 6.71 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.71 |
| Piotroski F-Score | 2 |